Panel: Genomics and Personalized Medicine in Biotech and Medical Devices

Domenick Bertelli.jpg

Domenick Bertelli,
Partner at Putnam Associates

Domenick is a Partner at Putnam Associates where he serves as a strategy consultant to biopharmaceutical, diagnostic and medical device clients.  He executes projects with strategic, quantitative and collaborative problem-solving components, including precision medicine strategies, product commercialization strategies, growth strategies, BD&L assessments, and market access and reimbursement analyses.  He has supported commercialization of more than 50 drugs, diagnostics, and devices.  Prior to Putnam, Domenick was an Engagement Manager at McKinsey, and an investment banker at BT Alex.Brown.  He earned his MBA in New Product & Venture Development at MIT Sloan, and his undergraduate degree in Government from Harvard.


Bhavesh Ashar
US Oncology Franchise Head at Sanofi Genzyme

Bhavesh Ashar leads the Oncology business at Sanofi Genzyme, and is responsible for establishing and executing a strategy for its continued success.  Bhavesh has been with Sanofi since 2002 and has held positions of increasing responsibility in sales and marketing, with a strong focus on Specialty markets.

Prior to joining Sanofi, Bhavesh served as an Engagement Manager with McKinsey & Company. He holds a BS in Mathematics from Imperial College in London and an MBA from the University of Chicago Booth School of Business


Dr. Paul de Bakker
Senior Director, Computational Genomics at Vertex

Paul de Bakker leads the Computational Genomics team within Human Biology at Vertex Pharmaceuticals to bolster the value of human genetics for the identification and validation of novel drug targets, patient responder populations and early response biomarkers/assays across its drug discovery portfolio.  Before his move to Vertex in 2015, he led academic research groups at the Brigham and Women's Hospital, Harvard Medical School, and the University Medical Center Utrecht, the Netherlands, with a focus on characterizing human genome sequence variation, developing computational tools for genetic analysis, and deciphering the genetic basis of complex traits.  He holds a PhD in structural biology and bioinformatics from the University of Cambridge, UK, and has a background in pharmacy.  

Birgit Schoeberl.jpg

Dr. Birgit Schoeberl
Head of Discovery-SVP at Merrimack Pharmaceuticals

Dr. Birgit Schoeberl leads early stage drug discovery and development programs as the Head of Discovery at Merrimack. She is an internationally recognized leader in the application of Systems Biology to biology and drug development. In her years at Merrimack, she has held leadership roles in the creation and development of many of Merrimack's clinical programs, most notably MM-121. Dr. Schoeberl was also one of the founding scientists of Silver Creek Pharmaceuticals, a majority owned subsidiary of Merrimack focused on the application of Systems Biology to regenerative medicine. She serves on Silver Creek’s Scientific Advisory Board and as an observer on their Board of Directors. Dr. Schoeberl also serves as a reviewer for multiple peer-reviewed journals, including Cell Systems, Science Signaling, and PLOS Computational Biology. She joined Merrimack in 2003 after doing postdoctoral training at the Massachusetts Institute of Technology where she built some of the earliest computational models of signaling networks. Dr. Schoeberl earned her PhD in Systems Biology from the Max Planck Institute for Dynamics of Complex Technical Systems and a MS in chemical engineering from the University of Karlsruhe, both in Germany.

Robert Green Head Shot.png

Dr. Robert Green
Director of Genomes2People Research Program, Brigham and Women’s; Associate director for research at Partners personalized medicine

Robert C. Green, MD, MPH is a medical geneticist and physician-scientist who directs the Genomes2People Research Program in the Division of Genetics at Brigham and Women’s Hospital, the Broad Institute and Harvard Medical School. Dr. Green conducts empirical translational research around the medical, behavioral and economic outcomes associated with the implementation of genomic medicine. He co-chaired the Steering Committee of the CSER and NSIGHT research programs, which have over 20 NIH grants. Dr. Green is also a co-investigator on the recently awarded Partners site grants for the eMERGE program and the Precision Medicine Initiative. He is Associate Director for Research of Partners HealthCare Personalized Medicine and a member of the Executive Committee for the Partners BioBank.